Research Topics
Species | Ries KranseSummaryAffiliation: Helen Dowling Institute Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
A graphical device to represent the outcomes of a logistic regression analysisRies Kranse
Rotterdam Cancer Registry, Rotterdam, The Netherlands
Prostate 68:1674-80. 2008..Both models mentioned above are logistic regression models. Nomograms enable their use in daily clinical practice...
Pre-selection of patients for pressure-flow analysis based on the maximum flow rateRies Kranse
Department of Urology, Erasmus University Rotterdam, Urodynamics Room Ee1630, P O Box 1738, 3000 DR Rotterdam, The Netherlands
Eur Urol 42:506-15. 2002..In addition, the variables on which these effects depend are studied...- A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancerMonique J Roobol
Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
Eur Urol 57:79-85. 2010..Screening for prostate cancer (PC) is controversial due to uncertainties about its efficiency... - Towards an optimal interval for prostate cancer screeningPim J van Leeuwen
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
Eur Urol 61:171-6. 2012..The rate of decrease in advanced cancers is an estimate for determining prostate cancer (PCa) screening program effectiveness... - Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohortHeidi A van Vugt
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
Eur J Cancer 48:1809-15. 2012..Prediction models need validation to assess their value outside the development setting... - Increased non-prostate cancer death risk in clinically diagnosed prostate cancerPim J van Leeuwen
Department of Urology Public Health, Erasmus Medical Centre, Rotterdam Cancer Registry Rotterdam, Rotterdam, The Netherlands
BJU Int 110:188-94. 2012..Men with clinically diagnosed PC have an increased risk of death unrelated to PC itself, i.e., the excess mortality is based on an increased risk of dying from other neoplasm and diseases of the circulatory or respiratory system... - Metastatic disease of screen-detected prostate cancer : characteristics at diagnosisStijn Roemeling
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Cancer 107:2779-85. 2006..Risk stratification of screen-detected cancers at diagnosis has become more important for the anticipation and interpretation of changing incidence/mortality ratios... - Prediction of prostate cancer in unscreened men: external validation of a risk calculatorHeidi A van Vugt
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
Eur J Cancer 47:903-9. 2011..Prediction models need external validation to assess their value beyond the setting where the model was derived from... 
The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progressionCaroline Schroten
Department of Urology, Erasmus MC, Gravendijkwal 230, Rotterdam, The Netherlands
Cancer Immunol Immunother 61:905-10. 2012....- Does PSA velocity predict prostate cancer in pre-screened populations?Fritz H Schroder
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Eur Urol 49:460-5; discussion 465. 2006..An elevated PSA in secondary screens may indicate benign enlargement of the prostate rather than prostate cancer. In such cases the yearly rate of increase of PSA (PSA velocity [PSAV]) may improve the test characteristics of PSA... - Causes for variability in repeated pressure-flow measurementsRies Kranse
Department of Urology, Division of Urodynamics, Erasmus University Rotterdam, Rotterdam, The Netherlands
Urology 61:930-4; discussion 934-5. 2003..Rather, the pressure-flow study is the only currently available method to study and quantify the apparent within-patient variability in bladder outlet resistance and bladder contractility... - Disease-specific mortality may underestimate the total effect of prostate cancer screeningPim J van Leeuwen
Erasmus University Medical Centre, Rotterdam, The Netherlands
J Med Screen 17:204-10. 2010..To study the difference between the disease-specific and excess mortality rate in the European Randomized Study of Screening for Prostate Cancer section Rotterdam... - A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam)Monique J Roobol
Department of Urology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
Prostate 66:604-12. 2006..The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA>or=3.0 ng/ml as biopsy indication... - Should we replace the Gleason score with the amount of high-grade prostate cancer?Andre N Vis
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
Eur Urol 51:931-9. 2007..We investigated the predictive value of the amount of high-grade cancer (Gleason growth patterns 4/5) in the biopsy for prostate-specific antigen (PSA) and clinical relapse after radical prostatectomy... - Weak correlation between bladder outlet obstruction and probability to void to completionRies Kranse
Comprehensive Cancer Center, Rotterdam, The Netherlands
Urology 62:667-71. 2003..quot; A high probability of a postvoid residual urine volume may be assumed to indicate "relative BOO." By its very nature, the correlation between "relative BOO" and postvoid residual urine volume is good... - The incidence and risk factors of metachronous colorectal cancer: an indication for follow-upSanna A Mulder
Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands
Dis Colon Rectum 55:522-31. 2012..Patients with colorectal cancer are at risk for developing metachronous colorectal cancer. The purpose of posttreatment surveillance is to detect and remove premalignant lesions to prevent metachronous colorectal cancer... - Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policyStijn H de Vries
Department of Urology, Erasmus Medical Center and Comprehensive Cancer Center, Rotterdam, The Netherlands
J Urol 172:2193-6. 2004..We evaluated prostate cancer (PCa) characteristics at diagnosis and changes in prostatic specific antigen (PSA) with time in males with screening detected PCa that was initially managed with a watchful waiting policy... - Bladder outlet resistanceRies Kranse
Department of Urology/Urodynamics, Erasmus University Rotterdam, The Netherlands
J Urol 169:1007-10. 2003..It combines (or weights) 2 components (dependent and independent flow rates) without losing its power to predict post-void residual... - Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled studyRies Kranse
Department of Urology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
Int J Cancer 113:835-40. 2005..If future studies confirm that these observations translate into a slowing of disease progression, a dietary intervention may become an attractive option for prostate cancer treatment and prevention... - Relative bladder outlet obstructionRies Kranse
Department of Urology-Urodynamics, Erasmus University Rotterdam, Rotterdam, The Netherlands
J Urol 168:565-70. 2002..CONCLUSIONS: Instead of defining obstruction as an absolute level of bladder outlet resistance we suggest that it is better to define it relatively, that is as a level of bladder outlet resistance that depends on bladder contractility... - A more advanced clinical stage is positively correlated with an increased prostate cancer detection rateMonique J Roobol
Department of Urology, Dijkzigt Academic Hospital, Rotterdam, The Netherlands
Urology 59:91-6. 2002..Apparently, the extracapsular lesions seen by TRUS are primarily nonmalignant... - Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trialHarry J de Koning
Department of Public Health, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
Int J Cancer 97:237-44. 2002..The differences between countries seem to reflect both underlying prostate cancer incidence and screening policy. The trials have the power to show definitive results in 2005-2008... - Verification bias and the prostate-specific antigen test--is there a case for a lower threshold for biopsy?Fritz H Schroder
N Engl J Med 349:393-5. 2003